Immunosuppression, Inflammation, and Skin Cancer: Will Eczema Treatment Enhance Ultraviolet Light-Induced Skin Cancer?
MetadataShow full item record
Publisher:The Ohio State University
Series/Report no.:The Ohio State University. College of Biological Sciences Honors Theses; 2006
Eczema, specifically atopic dermatitis (AD), is a common condition characterized by skin inflammation with erythema and pruritis. Protopic (tacrolimus) and Elidel (pimecrolimus) are immunosuppressant drugs that have been introduced for the treatment of AD. Using the Skh-1 mouse model of ultraviolet light B (UVB) induced inflammation, we examined the effects of local immunosuppression following topical treatment with Elidel and Protopic on levels of cutaneous ultraviolet light mediated inflammation including neutrophil infiltration, COX-2 expression and PGE2 production. The goal of the studies was to determine whether topical treatment with these drugs in combination with UVB exposure would alter levels of inflammation, a process known to contribute to an increase in skin tumor development. The results of the current study demonstrate that the timing and number of topical treatments in relation to UVB exposure changes the inflammatory response in the skin. Repeated topical application of the immunosuppressants prior to UVB exposure resulted in changes in products that are indicators of future tumor development, including edema, neutrophil infiltration and activation as measured by myeloperoxidase (MPO) activity. The current study demonstrated that induction of COX-2 expression and PGE2 production is not responsible for the observed changes in skin inflammation. Advisor: Tatiana M. Oberyszyn